Comparative Pharmacology
Head-to-head clinical analysis: LINAGLIPTIN versus NESINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LINAGLIPTIN versus NESINA.
LINAGLIPTIN vs NESINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Linagliptin is a competitive, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing incretin hormones (GLP-1, GIP) levels, thereby enhancing glucose-dependent insulin secretion and suppressing glucagon release.
Inhibitor of dipeptidyl peptidase-4 (DPP-4), preventing inactivation of incretin hormones (GLP-1, GIP), thereby increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner.
5 mg orally once daily
25 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours, allowing once-daily dosing. No accumulation at steady state.
Clinical Note
moderateLinagliptin + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Linagliptin."
Clinical Note
moderateLinagliptin + Delavirdine
"The serum concentration of Delavirdine can be decreased when it is combined with Linagliptin."
Clinical Note
moderateLinagliptin + Clarithromycin
"The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Linagliptin."
Clinical Note
moderateLinagliptin + Ranolazine
Terminal elimination half-life: 12.4–26.1 hours (mean ~21 hours); supports once-daily dosing
Approximately 90% of absorbed dose is excreted unchanged in feces (biliary/fecal route), and about 5% is excreted unchanged in urine. Renal excretion is minimal (<1% as metabolites).
Renal: 87% (75% as unchanged drug, 12% as inactive metabolites); Fecal: <1%
Category A/B
Category C
DPP-4 Inhibitor
DPP-4 Inhibitor
"The serum concentration of Ranolazine can be increased when it is combined with Linagliptin."